Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT04664933
Recruiting Not applicable

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)

NCT04664933 · tracked via the Priya Life Science China tracker
Sponsor
Hui-Sheng Chen
Phase
Not applicable
Started
2020-12-01
Last updated
2026-09-11

Condition(s) studied

Stroke, IschemicIntravascular ThrombosisMechanical Thrombectomy

Investigational drug(s) / intervention(s)

Intra-arterial administration of neuroprotective agents

Intra-arterial administration of neuroprotective agents: Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min

Study summary

To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥18 years; 2. Acute ischemic stroke patients who is eligible for endovascular treatment; 3. Signed informed consent. Exclusion Criteria: 1. Modified Rankin Score \>2 caused by a history of prior stroke; 2. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\<80000/mm3); 3. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; 4. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg); 5. Unsuitable for this clinical studies assessed by researcher.

Primary outcome measure(s)

  • Proportion of server adverse events — 48 hours
    server adverse events including femoral artery dissection, local thrombosis, seudoaneurysm, arteriovenousfistula, etc.

Trial sites (1)

FacilityCityRegionStatus
Department of Neurology, General Hospital of Northern Theater Command Shenyang China Recruiting

More Hui-Sheng Chen trials in China

Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT) Recruiting
Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK) Recruiting

Other trials for the same condition

Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2) Recruiting
Evaluation and Prediction of the Effect of EECP on HR-NICE Patients Recruiting
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases Recruiting
Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke Recruiting
Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04664933 on ClinicalTrials.gov ↗ ← All trials in China